Section Arrow
GPCR.NASDAQ
- Structure Therapeutics
Quotes are at least 15-min delayed:2025/09/04 10:13 EDT
Regular Hours
Last
 19.225
-0.485 (-2.46%)
Day High 
20 
Prev. Close
19.71 
1-M High
21.436 
Volume 
63.31K 
Bid
19.16
Ask
19.29
Day Low
19.17 
Open
20 
1-M Low
15.8 
Market Cap 
1.14B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 19.22 
20-SMA 18.69 
50-SMA 18.95 
52-W High 45.37 
52-W Low 13.22 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.15/-5.40
Enterprise Value
1.14B
Balance Sheet
Book Value Per Share
13.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.0485-0.0041-7.79%-- 
PPBTPurple Biotech Ltd0.8747-0.5453-38.40%0PE
ETHZETHZilla Corporation2.355-0.165-6.55%-- 
SGMOSangamo Therapeutics0.4957-0.0383-7.17%-- 
RXRXRecursion Pharmaceuticals4.53-0.1-2.16%-- 
Quotes are at least 15-min delayed:2025/09/04 10:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leveragesboth structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable andoperating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.